Tyler Marciniak

Investor Relations Contact at TRANSCENTA HOLDING LIMITED

Health Technology

Consumer Services

Profile

Tyler Marciniak is SVP-Investor Relations & Corporate Communications at Transcenta Holding Ltd. since 2025.
Former roles include Director-Oncology Communications & Advocacy at Astellas Pharma, Inc. and VP-Investor Relations, Media & Operation at ACELYRIN, Inc. Education includes graduate studies at The Trustees of Columbia University in The City of New York and an MBA from Kellogg School of Management.

Tyler Marciniak active positions

Companies	Position	Start
TRANSCENTA HOLDING LIMITED	Investor Relations Contact	16/10/2025

All active positions of Tyler Marciniak

Former positions of Tyler Marciniak

Companies	Position	End
ACELYRIN, INC.	Investor Relations Contact	21/05/2025
ASTELLAS PHARMA INC.	Corporate Officer/Principal	-

See the detail of Tyler Marciniak's experience

Training of Tyler Marciniak

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Tyler Marciniak's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
The Trustees of Columbia University in The City of New York The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Astellas Pharma, Inc. Astellas Pharma, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceuticals and related medical products	Health Technology
Kellogg School of Management Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Transcenta Holding Ltd. Transcenta Holding Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company that manufactures and wholesales pharmaceutical products	Health Technology
ACELYRIN, Inc. ACELYRIN, Inc. Pharmaceuticals: MajorHealth Technology Operates as late-stage clinical biopharmaceutical company which focuses on identifying, acquiring and accelerating the development & commercialization of medicines	Health Technology